Nextel Medical Revises Reg A Offering to $0.001-$0.01, Adds 51% Voting Control Preferred Stock
MAJI has more than doubled off its 52-week low of $0.002 on light trading volume (0.2× avg).
Summary
Nextel Medical slashed its offering price to $0.001-$0.01 per share and revealed CEO Matthew Dwyer now holds a single preferred share with 51% voting control. The company has $177 in cash and cannot fund its pending $12.75M acquisition.
Key Events · Financing and Capital Events · MAJI
-
Offering Price Slashed to $0.001-$0.01
Remaining 27.9M company shares and 329K selling shareholder shares now offered at $0.001-$0.01, down from prior $0.15 selling shareholder price. Company has already sold 32.1M shares for $295,000.
-
CEO Gains 51% Voting Control
Matthew Dwyer received one share of Series C Convertible Preferred Stock in April 2026, carrying 51% of all votes and convertible into 51% of outstanding common stock. Series A and B preferred stock were eliminated.
-
Going Concern Warning
Company had only $177 in cash as of March 31, 2026, with a working capital deficit of $726,256. Financial statements include substantial doubt about ability to continue as a going concern.
-
Acquisition Funding Gap
Company cannot fund its $12.75M acquisition of Jumpstart Rx and Island 40 Group ($3.5M cash + $9.25M preferred stock). Audited financial statements for targets not yet completed.
Analysis · MAJI · Technology
Nextel Medical Corp. has amended its Regulation A offering to sell up to 60 million shares at a deeply discounted price of $0.001 to $0.01 per share, down from the prior $0.15 selling shareholder price. The company has already sold 32.1 million shares for $295,000 and is now offering the remaining 27.9 million shares at the new lower price. More critically, the filing reveals that CEO Matthew Dwyer was issued a single share of Series C Convertible Preferred Stock in April 2026 that carries 51% of all shareholder votes and converts into 51% of outstanding common stock — effectively giving him permanent control of the company. The company also disclosed it lacks the funds to complete its $12.75 million acquisition of Jumpstart Rx and Island 40 Group, and its financial statements contain a going concern warning with only $177 in cash as of March 31, 2026.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MAJI was trading at $0.01 on OTC in the Technology sector, with a market capitalization of approximately $552.4K. The 52-week trading range was $0.00 to $0.21. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.